Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : NVS save search
Europe Frontotemporal Dementia Market Research Report 2023: Growing Prevalence of Dementia & Increasing Number of Clinical Trials - Competition, Forecasts & Opportunities to 2028
Published: 2023-04-26 (Crawled : 15:20) - prnewswire.com
GLAXF | $20.07 -14.18% 1K
|
Health Technology
|
| O: -4.57%
H: 0.22%
C: -1.98%
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
VTRS | $11.32 -0.09% -0.09% 4.4M
|
Health Technology
|
| O: 0.22%
H: 0.65%
C: -1.09%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.62%
H: 0.0%
C: -2.04%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: -0.66%
H: 0.18%
C: -0.9%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: -0.03%
H: 0.3%
C: -2.63%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
CNTG | $0.5555 -11.21% 87K
|
Commercial Services
|
| O: 1.23%
H: 27.27%
C: -15.76%
europe report dementia trials research growing market
Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
Published: 2021-08-05 (Crawled : 12:00) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 1.32%
H: 2.47%
C: 2.35%
NTLA | $22.9 -5.65% -5.98% 1.6M
|
Health Technology
|
| O: -2.46%
H: 24.2%
C: 15.24%
financial results results
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
Published: 2022-03-08 (Crawled : 17:00) - voyagertherapeutics.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
VYGR | $8.25 -2.14% -2.18% 450K
|
Health Technology
|
| O: 31.15%
H: 19.58%
C: 9.17%
therapeutics report results
Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
Published: 2022-03-08 (Crawled : 07:00) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
VYGR | $8.25 -2.14% -2.18% 450K
|
Health Technology
|
| O: 31.15%
H: 19.58%
C: 9.17%
trace novartis aav capsids gene therapy program license therapeutics therapy
2023 Inhalers Pipeline Research Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies
Published: 2024-01-17 (Crawled : 18:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.78%
H: 0.59%
C: 0.57%
VRNA | $15.82 -0.57% -0.57% 320K
|
Health Technology
|
| O: 0.52%
H: 2.31%
C: -0.87%
NKTR | $1.56 -6.59% -7.05% 2.8M
|
Health Technology
|
| O: -0.73%
H: 12.24%
C: 12.24%
companies report pipeline research key
REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights
Published: 2021-08-09 (Crawled : 20:00) - prnewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.35%
H: 0.33%
C: 0.15%
QURE | $4.75 -0.63% -0.63% 670K
|
Health Technology
|
| O: 0.07%
H: 1.15%
C: -0.03%
RARE | $42.87 -8.79% -9.63% 1.7M
|
Health Technology
|
| O: 1.14%
H: 1.44%
C: 0.89%
RGNX | $18.04 -0.28% -0.28% 350K
|
Health Technology
|
| O: -11.65%
H: 11.75%
C: 9.11%
financial results results
Global CAR T-Cell Therapy Market Analysis Report 2023: Drug type, Indication, Target Antigen, End-user and Region - Forecast to 2030
Published: 2024-01-24 (Crawled : 17:00) - prnewswire.com
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.39%
H: 0.82%
C: -0.74%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.22%
H: 0.43%
C: -0.39%
GILD | $67.76 -1.3% -1.31% 7.7M
|
Health Technology
|
| O: 0.1%
H: 0.43%
C: -0.04%
AUTL | $4.9 -2.39% -2.45% 790K
|
Health Technology
|
| O: -0.91%
H: 11.52%
C: 4.94%
drug report t-cell global therapy market
RNAi Drug Delivery Market worth $109.73 billion between 2022-2027- Exclusive report by Technavio
Published: 2023-07-27 (Crawled : 08:00) - prnewswire.com
RNAZ | $0.5422 -12.73% -14.59% 3.5M
|
Professional, Scientific, and T...
|
| O: 2.57%
H: 3.43%
C: 0.47%
TMO | $557.87 -1.3% 0.0% 1M
|
Health Technology
|
| O: 0.17%
H: 0.35%
C: -2.67%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.7%
H: 0.12%
C: -0.76%
SLN | $20.67 -6.77% -7.26% 78K
|
Health Technology
|
| O: 2.61%
H: 0.27%
C: -2.18%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
BNTX | $87.88 1.62% 1.59% 750K
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: 0.0%
BNTC | $5.26 -4.36% -4.56% 30K
|
Health Technology
|
| O: -8.92%
H: 9.49%
C: 0.59%
drug report market
Soft Contact Lens Market: 40% of Growth to Originate from APAC, Evolving Opportunities with BenQ Corp. & Cantor and Nissel Ltd. - Technavio
Published: 2022-09-07 (Crawled : 08:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 4.71%
H: 0.0%
C: 0.0%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.66%
H: 0.88%
C: 0.8%
BHC | $8.63 -1.48% 0.0% 3.2M
|
Health Technology
|
| O: -0.15%
H: 9.26%
C: 7.25%
growth
REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights
Published: 2021-11-02 (Crawled : 20:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.7%
H: 0.82%
C: 0.82%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.59%
H: 0.67%
C: 0.4%
SLDB | $9.99 -3.66% -3.8% 150K
|
Health Technology
|
| O: 1.89%
H: 9.26%
C: 8.8%
RGNX | $18.04 -0.28% -0.28% 350K
|
Health Technology
|
| O: 4.62%
H: 1.4%
C: -1.41%
financial results results
Insights on the Non-Melanoma Skin Cancer Treatment Global Market to 2026 - by Treatment Type, Indication, End-use and Region
Published: 2021-11-01 (Crawled : 18:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 1.3%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: -0.17%
H: 1.58%
C: 0.65%
ICAD | $1.62 -4.14% -4.32% 110K
|
Technology Services
|
| O: 0.0%
H: 0.85%
C: -0.57%
ARAY | $2.31 1.32% 1.3% 760K
|
Health Technology
|
| O: 0.0%
H: 8.82%
C: 7.01%
treatment skin cancer cancer skin
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
Published: 2021-08-05 (Crawled : 11:00) - biospace.com/
WPP | $47.37 -0.25% 0.0% 490K
|
Commercial Services
|
| O: 3.0%
H: 1.2%
C: 0.85%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -0.09%
MRNA S | $103.86 -1.22% -1.23% 2.2M
|
Health Technology
|
| O: -2.23%
H: 8.36%
C: 1.6%
financial results results
Global Contact Lenses Market- Bausch Health Companies Inc., BenQ Materials Corp., Contamac Ltd., among others to contribute to the market growth |Industry Analysis, Market Trends, Opportunities and Forecast 2024
Published: 2021-03-11 (Crawled : 16:01) - prnewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.58%
H: 0.69%
C: 0.07%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: 0.25%
H: 0.68%
C: -0.25%
BHC | $8.63 -1.48% 0.0% 3.2M
|
Health Technology
|
| O: -2.53%
H: 8.07%
C: 7.47%
growth
BeiGene Reports First Quarter 2022 Financial Results
Published: 2022-05-05 (Crawled : 12:00) - biospace.com/
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.39%
H: 0.15%
C: -1.07%
BGNE S | $138.39 -2.06% -2.1% 230K
|
Health Technology
|
| O: 0.98%
H: 7.7%
C: -2.09%
results
Uveitis Drugs Market, High Prevalence Of Eye Disorders And Associated Risk Factors Of Uveitis to Boost Market Growth - Technavio
Published: 2022-08-08 (Crawled : 22:00) - prnewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 1.28%
H: 0.8%
C: 0.13%
BHC | $8.63 -1.48% 0.0% 3.2M
|
Health Technology
|
| O: -7.02%
H: 7.55%
C: -4.6%
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: 0.24%
H: 1.11%
C: -0.31%
BIIB | $196.76 -0.72% -0.72% 1.2M
|
Health Technology
|
| O: -0.56%
H: 1.04%
C: 0.58%
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: -0.03%
H: 1.02%
C: 0.47%
risk eye growth market
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2022-11-01 (Crawled : 12:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.13%
H: 0.0%
C: 0.0%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.68%
H: 1.05%
C: -0.23%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.47%
H: 0.09%
C: -0.55%
XNCR | $20.09 -1.9% -1.94% 390K
|
Health Technology
|
| O: 1.07%
H: 2.51%
C: -0.11%
MOR | $18.02 -0.22% -0.22% 640K
|
Health Technology
|
| O: 3.1%
H: 1.8%
C: -0.6%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 1.59%
H: 7.26%
C: 1.89%
financial results
Cellular Immunotherapy Market Research Report by Type, Indication, Technology Type, End Use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-11-10 (Crawled : 17:00) - prnewswire.com
GLAXF | $20.07 -14.18% 1K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
AZNCF | $138.88 -4.19% 960
|
Health Technology
|
| O: 6.22%
H: 3.13%
C: -0.56%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 2.81%
H: 0.43%
C: -0.2%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: 2.59%
H: 0.72%
C: 0.63%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: 1.22%
H: 0.01%
C: -1.7%
IOVA | $11.89 -3.8% -3.95% 6.4M
|
Health Technology
|
| O: 6.12%
H: 4.99%
C: 4.21%
INO | $11.0 -0.27% -0.27% 260K
|
Health Technology
|
| O: 5.5%
H: 4.35%
C: 3.48%
GILD | $67.76 -1.3% -1.31% 7.7M
|
Health Technology
|
| O: 1.43%
H: 0.36%
C: -1.08%
ATRA | $0.7007 -1.03% -1.04% 1.7M
|
Health Technology
|
| O: 2.58%
H: 23.12%
C: 20.85%
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
|
| O: 7.08%
H: 0.84%
C: -0.43%
ADAP | $1.065 -8.19% -8.92% 1.3M
|
Health Technology
|
| O: 0.0%
H: 7.14%
C: 5.71%
covid-19 research global immunotherapy report impact technology market
USD 8 Bn growth opportunity in HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market | North America to emerge as key market | Technavio
Published: 2022-05-25 (Crawled : 04:00) - prnewswire.com
AZNCF | $138.88 -4.19% 960
|
Health Technology
|
| O: -1.42%
H: 2.73%
C: 2.73%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
VTRS | $11.32 -0.09% -0.09% 4.4M
|
Health Technology
|
| O: -0.26%
H: 3.13%
C: 2.96%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
PBYI | $5.35 1.52% 1.5% 270K
|
Health Technology
|
| O: -1.6%
H: 6.52%
C: 3.8%
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
|
| O: -0.45%
H: 0.89%
C: 0.54%
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: 1.42%
H: 0.72%
C: 0.0%
america growth market her2- her2
Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
Published: 2021-03-16 (Crawled : 01:00) - biospace.com/
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.14%
H: 0.82%
C: 0.7%
CELC | $18.09 -1.2% -1.22% 110K
|
Commercial Services
|
| O: 1.19%
H: 6.37%
C: 0.66%
new drug collaboration cancer biotech drug iot breast cancer trial
Global Lupus Therapeutic Market to Surpass US$ 5,408.1 Million by 2030, Says Coherent Market Insights
Published: 2022-03-16 (Crawled : 18:00) - prnewswire.com
GLAXF | $20.07 -14.18% 1K
|
Health Technology
|
| O: -0.46%
H: 3.49%
C: 3.49%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.25%
H: 0.0%
C: 0.0%
UCBJY | $63.874 -4.38% 11K
|
Manufacturing
|
| O: 1.41%
H: 2.33%
C: 0.04%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 2.07%
H: 1.62%
C: 1.56%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: 0.26%
H: 0.31%
C: -0.39%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
AUPH | $5.045 -1.08% -1.09% 1.3M
|
Health Technology
|
| O: 0.95%
H: 6.23%
C: 5.19%
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: -0.37%
lupus market
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.